Fetal Diagnosis and Therapy

Original Paper

Maternal Serum Alpha-Fetoprotein in Normal Pregnancy at 11–13 Weeks’ Gestation

Bredaki F.E.a · Wright D.c · Akolekar R.a · Cruz G.a · Nicolaides K.H.a, b

Author affiliations

aHarris Birthright Research Centre for Fetal Medicine, King’s College Hospital and bDepartment of Fetal Medicine, University College Hospital, London, and cSchool of Computing and Mathematics, University of Plymouth, Plymouth, UK

Keywords: First-trimester screeningAlpha-FetoproteinFree β-hCGPyramid of prenatal carePAPP-A

Related Articles for ""
Fetal Diagn Ther 2011;30:274–279
https://doi.org/10.1159/000330200

Log in to MyKarger to check if you already have access to this content.




Forgot your password
Sign up to MyKarger

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more
CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates

Select
* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: May 16, 2011
Accepted: June 19, 2011
Published online: December 08, 2011
Issue release date: December 2011

Number of Print Pages: 6
Number of Figures: 3
Number of Tables: 4

ISSN: 1015-3837 (Print)
eISSN: 1421-9964 (Online)

For additional information: https://www.karger.com/FDT

Abstract

Objective: To establish a reference distribution of maternal serum alpha-fetoprotein (AFP) at 11–13 weeks’ gestation and define the contribution of maternal variables that influence the measured concentration of AFP. Methods: Serum concentration of AFP at 11–13 weeks was measured in 1,500 singleton pregnancies which were not complicated by hypertensive disorders or diabetes mellitus and resulted in the live birth at or after 37 weeks of phenotypically normal neonates with birth weights above the 5th and below the 95th percentile. Multiple regression analysis was used to account for maternal characteristics that influence the measured concentration of AFP and a distribution of log multiples of the median (MoM) values was fitted. Results: Log10 AFP increased with gestational age, decreased with maternal weight and was significantly affected by maternal racial origin, smoking status and method of conception. Compared with values in Caucasian women who were non-smokers and conceived spontaneously, AFP MoM was on average 23% higher in Afro-Caribbeans and 8% lower in East Asians, 11% higher in smokers and 10% higher in those conceiving by in vitro fertilization. Conclusion: In normal pregnancies at 11–13 weeks, serum AFP increases with gestational age and is affected by maternal race, weight, smoking status and method of conception.

© 2011 S. Karger AG, Basel

References

  1. Merkatz IR, Nitowsky HM, Macri JN, Johnson WE: An association between low maternal serum alpha-fetoprotein and fetal chromosomal abnormalities. Am J Obstet Gynecol 1984;148:886–894.
    External Resources
  2. Cuckle HS: Biochemical screening for Down syndrome. Eur J Obstet Gynecol Rep Biol 2000;92:97–101.
    External Resources
  3. Wald NJ, Cuckle H, Brock JH, Peto R, Polani PE, Woodford FP: Maternal serum-alpha-fetoprotein measurement in antenatal screening for anencephaly and spina bifida in early pregnancy. Report of U.K. collaborative study on alpha-fetoprotein in relation to neural-tube defects. Lancet 1977;1:1323–1332.
    External Resources
  4. Dugoff L, Hobbins JC, Malone FD, Vidaver J, Sullivan L, Canick JA, Lambert-Messerlian GM, Porter TF, Luthy DA, Comstock CH, Saade G, Eddleman K, Merkatz IR, Craigo SD, Timor-Tritsch IE, Carr SR, Wolfe HM, D’Alton ME; FASTER Trial Research Consortium: Quad screen as a predictor of adverse pregnancy outcome. Obstet Gynecol 2005;106:260–267.
    External Resources
  5. Huang T, Hoffman B, Meschino W, Kingdom J, Okun N: Prediction of adverse pregnancy outcomes by combinations of first and second trimester biochemistry markers used in the routine prenatal screening of Down syndrome. Prenat Diagn 2010;30:471–477.
    External Resources
  6. Nicolaides KH, Campbell S, Gabbe SG, Guidetti R: Ultrasound screening for spina bifida: cranial and cerebellar signs. Lancet 1986;2:72–74.
    External Resources
  7. Ghi T, Pilu G, Falco P, Segata M, Carletti A, Cocchi G, Sanini D, Bonasoni P, Tani G, Rizzo N: Prenatal diagnosis of open and closed spina bifida. Ultrasound Obstet Gynecol 2006;28:899–903.
    External Resources
  8. Snijders RMJ, Noble P, Sebire N, Souka A, Nicolaides KH: UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal translucency thickness at 10–14 weeks of gestation. Lancet 1998;351:343–346.
    External Resources
  9. Nicolaides KH: Screening for fetal aneuploidies at 11 to 13 weeks. Prenat Diagn 2011;31:7–15.
    External Resources
  10. Beta J, Bredaki FE, Calvo JR, Akolekar R, Nicolaides KH: Maternal serum α-fetoprotein at 11–13 weeks’ gestation in spontaneous early preterm delivery. Fetal Diagn Ther 2011;30:88–93.
    External Resources
  11. Cuckle HS, van Lith JMM: Appropriate biochemical parameters in first-trimester screening for Down syndrome. Prenat Diagn 1999;19:505–512.
    External Resources
  12. Kagan KO, Wright D, Spencer K, Molina FS, Nicolaides KH: First-trimester screening for trisomy 21 by free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A: impact of maternal and pregnancy characteristics. Ultrasound Obstet Gynecol 2008;31:493–502.
    External Resources
  13. Robinson HP, Fleming JE: A critical evaluation of sonar ‘crown-rump length’ measurements. Br J Obstet Gynaecol 1975;82:702–710.
    External Resources
  14. Draper NR, Smith H: Applied Regression Analysis, ed 2. John Wiley and Sons Ltd., USA, 1981.
  15. Macri JN, Weiss RR, Elligers KW, Federgreen WR: Racial differences in maternal serum-alpha-fetoprotein. Lancet 1976;1:207–208.
    External Resources
  16. Crandall BF, Lebherz TB, Schroth PC, Matsumoto M: Alpha-fetoprotein concentrations in maternal serum: relation to race and body weight. Clin Chem 1983;29:531–533.
    External Resources
  17. Baumgarten A: Racial difference and biological significance of maternal serum alpha-fetoprotein. Lancet 1986;2:573.
    External Resources
  18. Benn PA, Clive JM, Collins R: Medians for second-trimester maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol; differences between races or ethnic groups. Clin Chem 1997;43:333–337.
    External Resources
  19. O’Brien JE, Dvorin E, Drugan A, Johnson MP, Yaron Y, Evans MI. Race-ethnicity-specific variation in multiple-marker biochemical screening: alpha-fetoprotein, hCG, and estriol. Obstet Gynecol 1997;89:355–358.
    External Resources
  20. Thomsen SG, Isager-Sally L, Lange AP, Saurbrey N, Schiølier V. Smoking habits and maternal serum alpha-fetoprotein levels during the second trimester of pregnancy. Br J Obstet Gynaecol 1983;90:716–717.
    External Resources
  21. Cuckle HS, Wald NJ, Densem JW, Royston P, Knight GJ, Haddow JE, Palomaki GE: The effect of smoking in pregnancy on maternal serum alpha-fetoprotein, unconjugated oestriol, human chorionic gonadotrophin, progesterone and dehydroepiandrosterone sulphate levels. Br J Obstet Gynaecol 1990;97:272–274.
    External Resources
  22. Bartels I, Hoppe-Sievert B, Bockel B, Herold S, Caesar J: Adjustment formulae for maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated oestriol to maternal weight and smoking. Prenat Diagn 1993;13:123–130.
    External Resources
  23. Spencer K: The influence of smoking on maternal serum AFP and free beta hCG levels and the impact on screening for Down syndrome. Prenat Diagn 1998;18:225–234.
    External Resources
  24. Perona M, Mancini G, Dall’Amico D, Guaraldo V, Carbonara A: Influence of smoking habits on Down’s syndrome risk evaluation at mid-trimester through biochemical screening. Int J Clin Lab Res 1998;28:179–182.
    External Resources
  25. Hafner E, Stangl G, Rosen A, Schuchter K, Plattner M, Philipp K: Influence of cigarette-smoking on the result of the triple test. Gynecol Obstet Invest 1999;47:188–190.
    External Resources
  26. Crossley JA, Aitken DA, Waugh SM, Kelly T, Connor JM: Maternal smoking: age distribution, levels of alpha-fetoprotein and human chorionic gonadotrophin, and effect on detection of Down syndrome pregnancies in second-trimester screening. Prenat Diagn 2002;22:247–255.
    External Resources
  27. Rudnicka AR, Wald NJ, Huttly W, Hackshaw AK: Influence of maternal smoking on the birth prevalence of Down syndrome and on second trimester screening performance. Prenat Diagn 2002;22:893–897.
    External Resources
  28. Barkai G, Goldman B, Ries L, Chaki R, Dor J, Cuckle H: Down’s syndrome screening marker levels following assisted reproduction. Prenat Diagn 1996;16:1111–1114.
    External Resources
  29. Ribbert LS, Kornman LH, De Wolf BT, Simons AH, Jansen CA, Beekhuis JR, Mantingh A: Maternal serum screening for fetal Down syndrome in IVF pregnancies. Prenat Diagn 1996;16:35–38.
    External Resources
  30. Frishman GN, Canick JA, Hogan JW, Hackett RJ, Kellner LH, Saller DN Jr: Serum triple-marker screening in in vitro fertilization and naturally conceived pregnancies. Obstet Gynecol 1997;90:98–101.
    External Resources
  31. Wald NJ, White N, Morris JK, Huttly WJ, Canick JA: Serum markers for Down’s syndrome in women who have had in vitro fertilisation: implications for antenatal screening. Br J Obstet Gynaecol 1999;106:1304–1306.
    External Resources
  32. Lam YH, Yeung WS, Tang MH, Ng EH, So WW, Ho PC: Maternal serum alpha-fetoprotein and human chorionic gonadotrophin in pregnancies conceived after intracytoplasmic sperm injection and conventional in-vitro fertilization. Hum Reprod 1999;14:2120–2123.
    External Resources
  33. Bar-Hava I, Yitzhak M, Krissi H, Shohat M, Shalev J, Czitron B, Ben-Rafael Z, Orvieto R: Triple-test screening in in vitro fertilization pregnancies. J Assist Reprod Genet 2001;18:226–229.
    External Resources
  34. Maymon R, Shulman A: Comparison of triple serum screening and pregnancy outcome in oocyte donation versus IVF pregnancies. Hum Reprod 2001;16:691–695.
    External Resources
  35. Perheentupa A, Ruokonen A, Tuomivaara L, Ryynänen M, Martikainen H: Maternal serum beta-HCG and alpha-fetoprotein concentrations in singleton pregnancies following assisted reproduction. Hum Reprod 2002;17:794–797.
    External Resources
  36. Maymon R, Shulman A: Serial first- and second-trimester Down’s syndrome screening tests among IVF-versus naturally-conceived singletons. Hum Reprod 2002;17:1081–1085.
    External Resources
  37. Räty R, Virtanen A, Koskinen P, Anttila L, Forsström J, Laitinen P, Mörsky P, Tiitinen A, Ekblad U: Serum free beta-HCG and alpha-fetoprotein levels in IVF, ICSI and frozen embryo transfer pregnancies in maternal mid-trimester serum screening for Down’s syndrome. Hum Reprod 2002;17:481–484.
    External Resources
  38. Muller F, Dreux S, Lemeur A, Sault C, Desgrès J, Bernard MA, Giorgetti C, Lemay C, Mirallié S, Beauchet A; French Collaborative Group: Medically assisted reproduction and second-trimester maternal serum marker screening for Down syndrome. Prenat Diagn 2003;23:1073–1076.
    External Resources
  39. Rice JD, McIntosh SF, Halstead AC: Second-trimester maternal serum screening for Down syndrome in in vitro fertilization pregnancies. Prenat Diagn 2005;25:234–238.
    External Resources
  40. Jauniaux, E, Burton, GJ: The effect of smoking in pregnancy on early placental morphology. Obstet Gynecol 1992;79:645–648.
    External Resources
  41. Demir R, Demir AY, Yinanc M: Structural changes in placental barrier of smoking mother. Path Res Pract 1994;190:656–667.
    External Resources
  42. Genabacev O, Bass KE, Joslin RJ, Fisher SJ: Maternal smoking inhibits early human cytotrophoblast differentiation. Reprod Toxicol 1995;9:245–255.
    External Resources

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: May 16, 2011
Accepted: June 19, 2011
Published online: December 08, 2011
Issue release date: December 2011

Number of Print Pages: 6
Number of Figures: 3
Number of Tables: 4

ISSN: 1015-3837 (Print)
eISSN: 1421-9964 (Online)

For additional information: https://www.karger.com/FDT

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Article Tools
Article Details

2011, Vol.30, No. 4

December 2011

Article

TAP Icon This Article is Part of
Recommend This
TOP